Previous 10 | Next 10 |
2023-05-11 18:30:54 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q1 2023 Earnings Call May 11, 2023 , 10:30 a.m. ET Operator Continue reading For further details see: Geron (GERN) Q1 2023 Earnings Call Transcript
2023-05-11 13:38:05 ET Geron Corporation (GERN) Q1 2023 Results Conference Call May 11, 2023 10:30 AM ET Company Participants Aron Feingold - VP, IR and Corporate Communications Dr. John Scarlett - Chairman and CEO Olivia Bloom - EVP and CFO Dr. Faye Feller -...
Longer follow-up data for 1-year transfusion independence (TI) in IMerge Phase 3, which demonstrated statistically significant and clinically meaningful continuous, durable efficacy Strong correlation of reduction in MDS-associated mutations with clinical benefits, including TI duration, prov...
2023-05-11 09:01:23 ET With its Q1 financials for 2023, Geron Corporation ( NASDAQ: GERN ) announced Thursday that the company is preparing for a potential commercial launch of its blood cancer therapy imetelstat ahead of its plans to submit a marketing application next month. E...
2023-05-11 08:04:47 ET Geron press release ( NASDAQ: GERN ): Q1 GAAP EPS of -$0.07 beats by $0.03 . For further details see: Geron GAAP EPS of -$0.07 beats by $0.03
Planned submission of U.S. New Drug Application on track for June 2023 Additional data and analyses from IMerge Phase 3 expected to be presented at upcoming medical meetings further strengthen differentiating qualities of imetelstat Preparations for potential commercial launch in ...
2023-05-10 11:12:09 ET Major earning expected before the bell on Thursday include: Fiverr International ( FVRR ) Himax Technologies ( HIMX ) JD.com ( JD ) Marathon Digital Holdings ( MARA ) Tapestry ( TPR ) For further details see: Notable...
2023-05-10 07:00:00 ET Summary Geron will report Q1 2023 earnings this Thursday 11th May. The company may be close to winning a first FDA approval for a drug in its >30-year history. Imetelstat is a differentiated drug that could secure an approval in lower risk MDS after s...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023 at 8:00 a.m. Eastern Time via press release, which will be available on the Company’s website at www....
2023-05-02 18:38:25 ET Summary Today, we circle back on Geron Corporation for the first time since last summer, as the small biopharma company is moving towards commercialization stage. The company has recently addressed its launch funding needs, has several milestones on the hori...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...